About Vermillion, Inc.
Vermillion, Inc. (formerly Ciphergen Biosystems, Inc.) is dedicated to the discovery, development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. Vermillion, along with its prestigious scientific collaborators, has ongoing diagnostic programs in oncology/hematology, cardiology and women's health with an initial focus in ovarian cancer. Based in Fremont, California, more information about Vermillion can be found on the Web at http://www.ciphergen.com and at http://www.vermillion.com
This press release contains "forward-looking" statements regarding
Vermillion (formerly Ciphergen), including statements with respect to the
anticipated closing of the private placement. Any statements contained in
this press release that are not historical facts may be deemed to be
forward- looking statements. The words "will," "expected," "intends" or
similar expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Vermillion's
results to differ materially from those indicated by these forward- looking
statements, including risks associated with the satisfaction of the
conditions to the closing of the private placement, as well as other risks
detailed from time to time in Vermillion's SEC reports, including its
Quarterly Report on Form 10-Q for the quarter ended June 30, 2007.
Vermillion does not undertake any obligation to update forward-looking
statements. You are encoura
|SOURCE Vermillion, Inc.|
Copyright©2007 PR Newswire.
All rights reserved